VIDEO: Skyrizi offers hope in refractory Crohn's

Issue: July 2021

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Remo Panaccione, MD, University of Calgary, tells Healio Gastroenterology that Skyrizi induced clinical remission and endoscopic response in patients with Crohn’s disease, according to results from the ADVANCE and MOTIVATE trials.

Published by:

Sources/Disclosures

Collapse

Disclosures: Panaccione reports consulting for AbbVie, Allergan, Amgen, Arena Pharma, BMS, Celgene, Gilead, Janssen, Lily, Pfizer, Sandoz and Takeda. Please see the study for all other authors’ relevant financial disclosures.

Read more about

inflammatory bowel disease

crohn's disease

risankizumab

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment